Literature DB >> 26674390

Novel mechanism of ghrelin therapy for cachexia.

Michiyoshi Hatanaka1, Masaaki Konishi2, Junnichi Ishida2, Masakazu Saito2, Jochen Springer2.   

Abstract

Entities:  

Year:  2015        PMID: 26674390      PMCID: PMC4670749          DOI: 10.1002/jcsm.12084

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


× No keyword cloud information.
I read with great interest the recent article by Ji-an Chen et al.1 Calorie intake is a major factor for the body composition including muscle mass.2 So, increase of food intake by the ghrelin administration in vivo could be one of the mechanisms for improvement of muscle wasting. In addition to that, this article showed the novel mechanism, which suggested that ghrelin administration could improve the muscle wasting induced by cisplatin in the skeletal muscle locally. Anamorelin HCl is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of cancer cachexia.3 Anamorelin enhanced body weight, tended to improve handgrip strength, increased appetite and quality of life, and decreased inflammatory markers from a phase 2 study.4,5 As patients were permitted to receive chemotherapy while on the study, therapeutic effect of anamorelin could be resulted from the effects on the tumor-induced and chemotherapy-induced muscle wasting. Judging from the aspect, the article suggests a novel mechanism that supports the clinical test partially. Another clinical trial suggested that the adverse effects of cachexia induced by cancer and chemotherapy cannot be recovered by additional nutrition alone.6 The trial supports the hypothesis that the appetite regulation would not be enough for cachexia therapy. On the other hand, ghrelin is known to have multi-actions, including not only increase in food intake but also decrease in energy expenditure and inflammation, increase in growth hormone and direct anabolic effect in skeletal muscles and adipose tissue.1,7–10 In addition to the increased appetite, some of these effects were confirmed in anamorelin trial.4,5 In order to make a better understanding of cachexia pathophysiology and therapeutic options for cachexia, it is important to understand the therapeutic mechanism of ghrelin and anamorelin in detail. For instance, it remains unclear whether ghrelin and anamorelin directly affected on the muscle cell in vivo and which action of ghrelin and anamorelin is the most important for the treatment of cachexia. Further advances are urgently needed.
  9 in total

1.  Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

Authors:  José M Garcia; Ralph V Boccia; Charles D Graham; Ying Yan; Elizabeth Manning Duus; Suzan Allen; John Friend
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

2.  Mechanisms of cisplatin-induced muscle atrophy.

Authors:  Hiroyasu Sakai; Atsunobu Sagara; Kazuhiko Arakawa; Ryoto Sugiyama; Akiko Hirosaki; Kazuhide Takase; Ara Jo; Ken Sato; Yoshihiko Chiba; Mitsuaki Yamazaki; Motohiro Matoba; Minoru Narita
Journal:  Toxicol Appl Pharmacol       Date:  2014-05-10       Impact factor: 4.219

3.  Ghrelin for cachexia.

Authors:  Takashi Akamizu; Kenji Kangawa
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

4.  Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia.

Authors:  Timo D Müller; Diego Perez-Tilve; Jenny Tong; Paul T Pfluger; Matthias H Tschöp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

5.  Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved.

Authors:  Ji-An Chen; Andres Splenser; Bobby Guillory; Jiaohua Luo; Meenal Mendiratta; Blaga Belinova; Tripti Halder; Guohua Zhang; Yi-Ping Li; Jose M Garcia
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-04-22       Impact factor: 12.910

6.  Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial.

Authors:  Isabelle Bourdel-Marchasson; Christelle Blanc-Bisson; Adélaïde Doussau; Christine Germain; Jean-Frédéric Blanc; Jérôme Dauba; Cyril Lahmar; Eric Terrebonne; Cédric Lecaille; Joël Ceccaldi; Laurent Cany; Sandrine Lavau-Denes; Nadine Houede; François Chomy; Jessica Durrieu; Pierre Soubeyran; Pierre Senesse; Geneviève Chene; Mariane Fonck
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

7.  Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.

Authors:  Claudio Pietra; Yasuhiro Takeda; Naoko Tazawa-Ogata; Masashi Minami; Xia Yuanfeng; Elizabeth Manning Duus; Robert Northrup
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-09-30       Impact factor: 12.910

8.  Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.

Authors:  Karsten Lenk; Sandra Palus; Robert Schur; Rakesh Datta; Jesse Dong; Michael D Culler; Stefan Anker; Jochen Springer; Gerhard Schuler; Volker Adams
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-18       Impact factor: 12.910

9.  Muscle wasting: an overview of recent developments in basic research.

Authors:  Sandra Palus; Stephan von Haehling; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-08-28       Impact factor: 12.910

  9 in total
  6 in total

Review 1.  Publication trends in cachexia and sarcopenia in elderly heart failure patients.

Authors:  Jochen Springer; Stefan D Anker
Journal:  Wien Klin Wochenschr       Date:  2016-11-24       Impact factor: 1.704

2.  Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure.

Authors:  Rocco Barazzoni; Gianluca Gortan Cappellari; Sandra Palus; Pierandrea Vinci; Giulia Ruozi; Michela Zanetti; Annamaria Semolic; Nicole Ebner; Stephan von Haehling; Gianfranco Sinagra; Mauro Giacca; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-11-03       Impact factor: 12.910

Review 3.  Skeletal muscle wasting in chronic heart failure.

Authors:  Tsuyoshi Suzuki; Sandra Palus; Jochen Springer
Journal:  ESC Heart Fail       Date:  2018-12-07

Review 4.  Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery.

Authors:  Cecilia T de Barros; Alessandra C Rios; Thaís F R Alves; Fernando Batain; Kessi M M Crescencio; Laura J Lopes; Aleksandra Zielińska; Patricia Severino; Priscila G Mazzola; Eliana B Souto; Marco V Chaud
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

Review 5.  Ghrelin for the management of cachexia associated with cancer.

Authors:  Mahalaqua Nazli Khatib; Anuraj H Shankar; Richard Kirubakaran; Abhay Gaidhane; Shilpa Gaidhane; Padam Simkhada; Zahiruddin Quazi Syed
Journal:  Cochrane Database Syst Rev       Date:  2018-02-28

Review 6.  Muscle wasting and sarcopenia in heart failure and beyond: update 2017.

Authors:  Jochen Springer; Joshua-I Springer; Stefan D Anker
Journal:  ESC Heart Fail       Date:  2017-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.